Metabolic Reprogramming via Targeting CD38 NADase Augments Adoptive T Cell Therapy

Abstract

One strategy to improve the potency of adoptive T cell therapy is to augment the function and persistence of anti-tumor T cells. In this issue of Cell Metabolism, Chatterjee et al. (2018) demonstrate that intratumoral CD4⁺ T cell functions and memory can be improved by targeting a CD38-NAD⁺-Sirt1-Foxo1 metabolic circuit.